Charles River Laboratories International, Inc. (Form: 8-K)  






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):   May 8, 2018

Charles River Laboratories International, Inc.
(Exact name of registrant as specified in its charter)

Delaware 001-15943 06-1397316
(State or other jurisdiction
(I.R.S. Employer
of incorporation) File Number) Identification No.)
251 Ballardvale St., Wilmington, Massachusetts   01887
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:   781-222-6000

Not Applicable
Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

Top of the Form

Item 5.07. Submission of Matters to a Vote of Security Holders

The Company held its Annual Meeting of Shareholders on May 8, 2018. For more information on the following proposals, see the Company’s proxy statement dated March 29, 2018. At the Company’s Annual Meeting, the following proposals were adopted by the votes specified below:

(a) The following eleven (11) directors were elected to serve until our 2019 Annual Meeting of Shareholders and received the number of votes listed opposite each of their names below:

    Number of Shares   Number of Shares   Number of Shares   Broker Non-Votes
    Voted For   Voted Against   Abstained        
James C. Foster
    39,761,241       1,397,969       322,119       2,313,982  
Robert J. Bertolini
    41,326,276       139,147       15,906       2,313,982  
Stephen D. Chubb
    40,546,667       919,770       14,892       2,313,982  
Deborah T. Kochevar
    40,763,577       703,538       14,214       2,313,982  
Martin W. MacKay
    41,350,551       115,235       15,543       2,313,982  
Jean-Paul Mangeolle
    41,274,380       192,738       14,211       2,313,982  
George E. Massaro
    40,639,756       826,089       15,484       2,313,982  
George M. Milne, Jr.
    35,277,811       6,146,118       57,400       2,313,982  
C. Richard Reese
    40,917,952       548,164       15,213       2,313,982  
Craig B. Thompson
    40,848,845       618,573       13,911       2,313,982  
Richard F. Wallman
    40,300,829       1,165,257       15,243       2,313,982  

(b) The shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers.

For   Against   Abstain   Broker Non-Votes
    1,545,723       57,334       2,313,982  

(c) The shareholders approved the 2018 Incentive Plan.

For   Against   Abstain   Broker Non-Votes
    4,278,391       57,703       2,313,982  

(d) The shareholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as our independent auditors for fiscal 2018.

For   Against   Abstain   Broker Non-Votes
    716,460       17,190       0  

Computershare Trust Company, N.A., our transfer agent, acted as independent proxy tabulator and Inspector of Election at the Annual Meeting of Shareholders.

Top of the Form


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Charles River Laboratories International, Inc.
May 14, 2018   By:   Matthew L. Daniel
        Name: Matthew L. Daniel
        Title: Corporate Senior Vice President, Legal Compliance, Deputy General Counsel and Assistant Secretary